3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
71
Neoplasms
10
Skin Neoplasms
5
Neoplasm Metastasis
5
Colorectal Neoplasms
2
Brain Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Skin Diseases
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Laryngeal Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
binimetinib
2
Aminolevulinic Acid
2
methyl 5-aminolevulinate
1
encorafenib
1
Vemurafenib
1
Radiotherapy
1
Radiation
1
Photochemotherapy
1
Fluorouracil
1
Floderm topical cream
1
Equipment and Supplies
1
Dacarbazine
1
BF-200 ALA
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Diseases
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT01909453
2026-02-27
COLUMBUS
Pfizer
Phase 3
Completed
921 enrolled
48 charts
1 FDA